These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 31466602)

  • 1. Pathogen Reduction: The State of the Science in 2019.
    Gehrie EA; Rutter SJ; Snyder EL
    Hematol Oncol Clin North Am; 2019 Oct; 33(5):749-766. PubMed ID: 31466602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Universal implementation of pathogen inactivation in labile blood products is a major step towards transfusion safety].
    Cazenave JP
    Bull Acad Natl Med; 2010 Dec; 194(9):1707-19; discussion 1719-20. PubMed ID: 22043595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the use of pathogen-reduced human plasma and platelet concentrates.
    Seltsam A; Müller TH
    Br J Haematol; 2013 Aug; 162(4):442-54. PubMed ID: 23710899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Blood - surely but safely!].
    Offergeld R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 Aug; 55(8):905-6. PubMed ID: 22842882
    [No Abstract]   [Full Text] [Related]  

  • 5. Multilayer-strategy to enhance optimal safety of the blood supply: The role of pathogen inactivation for optimizing recipient safety and helping health care cost containment: Moderator views.
    Seghatchian J
    Transfus Apher Sci; 2015 Apr; 52(2):233-6. PubMed ID: 25748230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogen reduction and blood transfusion safety in Africa: strengths, limitations and challenges of implementation in low-resource settings.
    Ware AD; Jacquot C; Tobian AAR; Gehrie EA; Ness PM; Bloch EM
    Vox Sang; 2018 Jan; 113(1):3-12. PubMed ID: 29193128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efforts Toward Elimination of Infectious Agents in Blood Products.
    Jacquot C; Delaney M
    J Intensive Care Med; 2018 Oct; 33(10):543-550. PubMed ID: 29562814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reasons for moving toward a patient-centric paradigm of clinical transfusion medicine practice.
    Vamvakas EC
    Transfusion; 2013 Apr; 53(4):888-901. PubMed ID: 22882177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood-Borne Pathogens: A Canadian Blood Services Centre for Innovation Symposium.
    Walsh GM; Shih AW; Solh Z; Golder M; Schubert P; Fearon M; Sheffield WP
    Transfus Med Rev; 2016 Apr; 30(2):53-68. PubMed ID: 26962008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogen reduction technique for fresh-frozen plasma, cryoprecipitate, and plasma fraction minipools prepared in disposable processing bag systems.
    Burnouf T; Radosevich M; El-Ekiaby M; Goubran H
    Transfusion; 2011 Feb; 51(2):446-7; author reply 447-8. PubMed ID: 21309785
    [No Abstract]   [Full Text] [Related]  

  • 11. Pathogen inactivation: coming of age.
    Lozano M; Cid J
    Curr Opin Hematol; 2013 Nov; 20(6):540-5. PubMed ID: 24104416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?
    Di Minno G; Navarro D; Perno CF; Canaro M; Gürtler L; Ironside JW; Eichler H; Tiede A
    Ann Hematol; 2017 Aug; 96(8):1253-1270. PubMed ID: 28624906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dried plasma: state of the science and recent developments.
    Pusateri AE; Given MB; Schreiber MA; Spinella PC; Pati S; Kozar RA; Khan A; Dacorta JA; Kupferer KR; Prat N; Pidcoke HF; Macdonald VW; Malloy WW; Sailliol A; Cap AP
    Transfusion; 2016 Apr; 56 Suppl 2():S128-39. PubMed ID: 27100749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation.
    Allain JP; Bianco C; Blajchman MA; Brecher ME; Busch M; Leiby D; Lin L; Stramer S
    Transfus Med Rev; 2005 Apr; 19(2):110-26. PubMed ID: 15852240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Can virus safety of blood products be assured?].
    Krusius T
    Duodecim; 1994; 110(13):1227-30. PubMed ID: 7497931
    [No Abstract]   [Full Text] [Related]  

  • 16. The Impact of Emerging Infectious Diseases on Chinese Blood Safety.
    He M; Wang J; Chen L; Liu J; Zeng P
    Transfus Med Rev; 2017 Apr; 31(2):94-101. PubMed ID: 27923518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates.
    Seghatchian J; Hervig T; Putter JS
    Transfus Apher Sci; 2011 Aug; 45(1):75-84. PubMed ID: 21782517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How do we … integrate pathogen reduced platelets into our hospital blood bank inventory?
    Rutter S; Snyder EL
    Transfusion; 2019 May; 59(5):1628-1636. PubMed ID: 30883807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evolution of neonatal transfusion practices: current recommendations].
    Plaisant F
    Transfus Clin Biol; 2011 Apr; 18(2):262-8. PubMed ID: 21440478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands.
    Salunkhe V; van der Meer PF; de Korte D; Seghatchian J; Gutiérrez L
    Transfus Apher Sci; 2015 Feb; 52(1):19-34. PubMed ID: 25620756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.